How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?
What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?
Community PollStarted
What potential side effects do you highlight when discussing bimekizumab with patients?
53 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Dermatology · Medical College of Wisconsin
Answered on
Both IL-17 and IL-23 agents have demonstrated excellent efficacy for psoriasis. Choosing between them often comes down to access and insurance coverage.
With that being said, considerations include:
- Side effect profile: The side effect profile for both IL-23 and IL-17 agents is similar, with the exc...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Dermatology · Wake Forest University
Answered on
I let patients with severe psoriasis know that both IL-23 and IL-17 blocking drugs are wonderful, both very effective and both very safe. IL-23 drugs don't require as many shots and maybe a touch safer (with less risk of candidiasis and inflammatory bowel disease as near as I can tell). IL-17 drugs ...
Join for free or sign in to see the full answer